Drug name - Corlanor
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7879842 | AMGEN INC | Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(3 years from now) | |
| US7361650 | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(3 years from now) | |
| US7361649 | AMGEN INC | β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(3 years from now) | |
| US7867996 | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Dec, 2026
(4 years from now) | |
| CN1827602A | AMGEN INC | Of Ivabradine Hydrochloride Crystal Form, Preparation Method And Pharmaceutical Compositions Containing It |
Feb, 2026
(3 years from now) | |
| CN100402502C | AMGEN INC | Of Ivabradine Hydrochloride Crystal Form, Preparation Method And Pharmaceutical Compositions Containing It |
Feb, 2026
(3 years from now) | |
| CN1827600B | AMGEN INC | Beta-Crystalline Form Of Ivabradine Hydrochloride, Preparation Method Thereof And Pharmaceutical Compositions Containing It |
Feb, 2026
(3 years from now) | |
| CN1827600A | AMGEN INC | Of Ivabradine Hydrochloride Crystal Form, Preparation Method And Pharmaceutical Compositions Containing It |
Feb, 2026
(3 years from now) | |
| IN200600485I1 | AMGEN INC | Crystalline Form Of Ivabradine Hydrochloride, A Process For Its Preparation And Pharmaceutical Compositions Containing It |
Feb, 2026
(3 years from now) | |
| IN200600486I1 | AMGEN INC | Crystalline Form Of Ivabradine Hydrochloride, A Process For Its Preparaton And Pharmaceutical Compositions Containing It |
Feb, 2026
(3 years from now) | |
| IN269993B | AMGEN INC | Process For The Preparation Of The ß-Crystalline Form Of Ivabradine Hydrochloride |
Feb, 2026
(3 years from now) | |
| IN237447B | AMGEN INC | A Process For The Preparation Of The Y-Crystalline Form Of Ivabradine Hydtochloride And Its Composition |
Feb, 2026
(3 years from now) | |
| EP1707562A1 | AMGEN INC | Crystalline Form Gamma Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It |
Feb, 2026
(3 years from now) | |
| EP1695965B1 | AMGEN INC | Crystalline Form Beta Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It |
Feb, 2026
(3 years from now) | |
| EP1707562B1 | AMGEN INC | Crystalline Form Gamma Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It |
Feb, 2026
(3 years from now) | |
| EP1695965B9 | AMGEN INC | Crystalline Form Beta Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It |
Feb, 2026
(3 years from now) | |
| EP1695965A1 | AMGEN INC | Crystalline Form Beta Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It |
Feb, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7361649
(Pediatric) | AMGEN INC | β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Aug, 2026
(3 years from now) | |
|
US7879842
(Pediatric) | AMGEN INC | Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Aug, 2026
(3 years from now) | |
|
US7361650
(Pediatric) | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Aug, 2026
(3 years from now) | |
|
US7867996
(Pediatric) | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Jun, 2027
(4 years from now) | |
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 5MG BASE | TABLET;ORAL | Prescription |
| EQ 7.5MG BASE | TABLET;ORAL | Prescription |
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7361650 | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(3 years from now) | |
| US7361649 | AMGEN INC | β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(3 years from now) | |
| US7879842 | AMGEN INC | Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(3 years from now) | |
| US7867996 | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Dec, 2026
(4 years from now) | |
| CN1827602A | AMGEN INC | Of Ivabradine Hydrochloride Crystal Form, Preparation Method And Pharmaceutical Compositions Containing It |
Feb, 2026
(3 years from now) | |
| CN100402502C | AMGEN INC | Of Ivabradine Hydrochloride Crystal Form, Preparation Method And Pharmaceutical Compositions Containing It |
Feb, 2026
(3 years from now) | |
| CN1827600B | AMGEN INC | Beta-Crystalline Form Of Ivabradine Hydrochloride, Preparation Method Thereof And Pharmaceutical Compositions Containing It |
Feb, 2026
(3 years from now) | |
| CN1827600A | AMGEN INC | Of Ivabradine Hydrochloride Crystal Form, Preparation Method And Pharmaceutical Compositions Containing It |
Feb, 2026
(3 years from now) | |
| IN200600485I1 | AMGEN INC | Crystalline Form Of Ivabradine Hydrochloride, A Process For Its Preparation And Pharmaceutical Compositions Containing It |
Feb, 2026
(3 years from now) | |
| IN269993B | AMGEN INC | Process For The Preparation Of The ß-Crystalline Form Of Ivabradine Hydrochloride |
Feb, 2026
(3 years from now) | |
| IN200600486I1 | AMGEN INC | Crystalline Form Of Ivabradine Hydrochloride, A Process For Its Preparaton And Pharmaceutical Compositions Containing It |
Feb, 2026
(3 years from now) | |
| IN237447B | AMGEN INC | A Process For The Preparation Of The Y-Crystalline Form Of Ivabradine Hydtochloride And Its Composition |
Feb, 2026
(3 years from now) | |
| EP1707562A1 | AMGEN INC | Crystalline Form Gamma Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It |
Feb, 2026
(3 years from now) | |
| EP1695965B1 | AMGEN INC | Crystalline Form Beta Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It |
Feb, 2026
(3 years from now) | |
| EP1707562B1 | AMGEN INC | Crystalline Form Gamma Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It |
Feb, 2026
(3 years from now) | |
| EP1695965B9 | AMGEN INC | Crystalline Form Beta Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It |
Feb, 2026
(3 years from now) | |
| EP1695965A1 | AMGEN INC | Crystalline Form Beta Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It |
Feb, 2026
(3 years from now) | |
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 5MG/5ML (1MG/ML) | SOLUTION;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.